JP2004534084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534084A5 JP2004534084A5 JP2003506921A JP2003506921A JP2004534084A5 JP 2004534084 A5 JP2004534084 A5 JP 2004534084A5 JP 2003506921 A JP2003506921 A JP 2003506921A JP 2003506921 A JP2003506921 A JP 2003506921A JP 2004534084 A5 JP2004534084 A5 JP 2004534084A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- use according
- amino acid
- sequence
- hydrophobic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 150000001413 amino acids Chemical class 0.000 claims 18
- 235000001014 amino acid Nutrition 0.000 claims 16
- 229940024606 amino acid Drugs 0.000 claims 16
- 230000002209 hydrophobic effect Effects 0.000 claims 11
- 235000004279 alanine Nutrition 0.000 claims 7
- 208000035143 Bacterial infection Diseases 0.000 claims 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 5
- 230000000844 anti-bacterial effect Effects 0.000 claims 5
- 230000000845 anti-microbial effect Effects 0.000 claims 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000014759 maintenance of location Effects 0.000 claims 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 229960000310 isoleucine Drugs 0.000 claims 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000000813 microbial effect Effects 0.000 claims 3
- 206010017533 Fungal infection Diseases 0.000 claims 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 238000002802 antimicrobial activity assay Methods 0.000 claims 2
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 101800002011 Amphipathic peptide Proteins 0.000 claims 1
- 239000004475 Arginine Chemical group 0.000 claims 1
- 244000063299 Bacillus subtilis Species 0.000 claims 1
- 235000014469 Bacillus subtilis Nutrition 0.000 claims 1
- 241000186245 Corynebacterium xerosis Species 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000495778 Escherichia faecalis Species 0.000 claims 1
- 241000192125 Firmicutes Species 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29972601P | 2001-06-22 | 2001-06-22 | |
| PCT/CA2002/000936 WO2003000277A2 (en) | 2001-06-22 | 2002-06-21 | Antimicrobial peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004534084A JP2004534084A (ja) | 2004-11-11 |
| JP2004534084A5 true JP2004534084A5 (enExample) | 2006-01-05 |
Family
ID=23156022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506921A Pending JP2004534084A (ja) | 2001-06-22 | 2002-06-21 | 抗菌ペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20040235745A1 (enExample) |
| EP (1) | EP1401478A2 (enExample) |
| JP (1) | JP2004534084A (enExample) |
| CN (1) | CN1516598A (enExample) |
| AU (1) | AU2002317071B2 (enExample) |
| CA (1) | CA2451310C (enExample) |
| IL (1) | IL159274A0 (enExample) |
| WO (1) | WO2003000277A2 (enExample) |
| ZA (1) | ZA200309580B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5010798B2 (ja) | 2001-10-03 | 2012-08-29 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 自己免疫疾患を抑制するためのコポリマー、及びその使用方法 |
| WO2005049819A1 (ja) * | 2003-10-29 | 2005-06-02 | Toagosei Co., Ltd. | 抗菌ペプチド及びその利用 |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| GB0818074D0 (en) * | 2008-10-02 | 2008-11-05 | Lytix Biopharma As | Treatment of biofilms |
| US8303962B2 (en) | 2009-01-06 | 2012-11-06 | C3 Jian, Inc. | Antibacterial and antifungal peptides |
| US20120135917A1 (en) * | 2009-06-16 | 2012-05-31 | Eisaku Yoshihara | Anti-Gram Negative Bacteria Agent |
| PL2617707T3 (pl) * | 2010-08-27 | 2017-04-28 | Neopharm Co., Ltd. | Nowy związek przyspieszający wydzielanie peptydu przeciwdrobnoustrojowego pochodzenia ludzkiego, sposób jego wytwarzania i kompozycja zawierająca go jako składnik aktywny |
| WO2013124436A1 (en) * | 2012-02-23 | 2013-08-29 | University Of East London | Synthetic anti-microbial peptides with a minority of cationic and a majority hydrophobic side chains |
| US10507227B2 (en) | 2014-04-15 | 2019-12-17 | The Hospital For Sick Children | Cationic antimicrobial peptides |
| IT202000006481A1 (it) * | 2020-03-27 | 2021-09-27 | Sanidrink S R L | Condotti tubolari antimicrobici |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994306A (en) * | 1995-11-22 | 1999-11-30 | Intrabiotics Pharmaceuticals, Inc. | Fine-tuned protegrins |
| US5714577A (en) * | 1996-01-26 | 1998-02-03 | University Of Pittsburgh | Antimicrobial peptides |
| AU720405B2 (en) * | 1996-02-16 | 2000-06-01 | Regents Of The University Of California, The | Antimicrobial peptides and methods of use |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6180604B1 (en) * | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
| US6043220A (en) * | 1997-12-03 | 2000-03-28 | Intrabiotics Pharmaceuticals, Inc. | Threonine-containing protegrins |
| AU4253799A (en) * | 1998-06-12 | 2000-01-05 | Micrologix Biotech, Inc. | Cancer therapy with cationic peptides |
-
2002
- 2002-06-21 US US10/481,286 patent/US20040235745A1/en not_active Abandoned
- 2002-06-21 CN CNA028121910A patent/CN1516598A/zh active Pending
- 2002-06-21 WO PCT/CA2002/000936 patent/WO2003000277A2/en not_active Ceased
- 2002-06-21 AU AU2002317071A patent/AU2002317071B2/en not_active Ceased
- 2002-06-21 CA CA2451310A patent/CA2451310C/en not_active Expired - Lifetime
- 2002-06-21 IL IL15927402A patent/IL159274A0/xx unknown
- 2002-06-21 EP EP02744972A patent/EP1401478A2/en not_active Withdrawn
- 2002-06-21 JP JP2003506921A patent/JP2004534084A/ja active Pending
-
2003
- 2003-12-10 ZA ZA200309580A patent/ZA200309580B/xx unknown
-
2007
- 2007-06-11 US US11/761,117 patent/US20080234188A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2799706T3 (es) | Lipopéptidos de alta pureza, micelas de lipopéptidos y procesos para preparar los mismos | |
| US5470950A (en) | Biologically active amphiphilic peptide compositions and uses therefor | |
| AU657781B2 (en) | Novel biologically active peptide compositions and uses therefor | |
| JP2006507270A5 (enExample) | ||
| JPH08505854A (ja) | 修飾された末端を有するアミノ酸及びペプチド | |
| WO1997018827A1 (en) | Compositions and methods for the prevention and treatment of oral mucositis | |
| US5225399A (en) | Antimicrobial amphiphilic peptides | |
| US5424290A (en) | Biologically active peptides and uses therefor | |
| US5620954A (en) | Peptide compositions and uses therefor | |
| TWI403330B (zh) | 低血球溶解性之抗微生物胜肽、醫藥組成物及其用途 | |
| JP6124139B2 (ja) | 低赤血球溶解性の抗微生物ペプチド、医薬組成物およびその使用 | |
| US20170158736A1 (en) | Compositions and methods for treating mrsa infections and for sensitizing mrsa to beta-lactam antibiotics | |
| JP2017522280A (ja) | 特に獣医学分野用の消毒剤および抗微生物組成物 | |
| US5912231A (en) | Substitution analogues of magainin peptides | |
| JP2004534084A (ja) | 抗菌ペプチド | |
| US20200172570A1 (en) | Antimicrobial peptides and compositions, methods, articles & kits relating thereto | |
| US20050215481A1 (en) | Antimicrobial peptide, its analogs and antimicrobial composition comprising them | |
| ATE350395T1 (de) | Diastereomere peptide und diese umfassende arzneimittel | |
| EP0533795A1 (en) | Composition of and treatment with biologically active peptides having d-amino acid residues | |
| US8691773B2 (en) | Peptide compound with biological activity, its preparation and its applications | |
| JP2009502810A5 (enExample) | ||
| AU681117C (en) | Amino acids and peptides having modified terminals | |
| JPH06509062A (ja) | 新規なペプチド組成物およびその用途 |